Prestige Consumer Healthcare (PBH) Scheduled to Post Quarterly Earnings on Tuesday

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) will be issuing its quarterly earnings data after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of $1.14 per share for the quarter. Prestige Consumer Healthcare has set its FY 2024 guidance at 4.330-4.330 EPS.Investors that wish to register for the company's conference call can do so using this link.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.04 by $0.02. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The company had revenue of $282.74 million for the quarter, compared to analyst estimates of $280.25 million. During the same period in the prior year, the company posted $1.04 EPS. Prestige Consumer Healthcare's quarterly revenue was up 2.6% on a year-over-year basis. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Down 0.1 %

Shares of PBH stock traded down $0.05 during mid-day trading on Tuesday, reaching $69.95. 157,774 shares of the company were exchanged, compared to its average volume of 233,963. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09. The business's 50 day simple moving average is $71.12 and its 200 day simple moving average is $64.80. The company has a market capitalization of $3.47 billion, a P/E ratio of -42.65, a P/E/G ratio of 1.90 and a beta of 0.53. Prestige Consumer Healthcare has a fifty-two week low of $55.96 and a fifty-two week high of $75.31.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, February 10th. TheStreet raised shares of Prestige Consumer Healthcare from a "c+" rating to a "b-" rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and an average target price of $110.00.

Insider Activity at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 5,336 shares of the company's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $69.00, for a total transaction of $368,184.00. Following the completion of the transaction, the senior vice president now owns 15,934 shares in the company, valued at $1,099,446. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.60% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.